Veradigm (MDRX) 10-Q 5 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	1,124,804
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		186,559,297

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 90,655	$ 116,873
Accounts receivable, net of allowance of $34,649 and $31,266 as of June 30, 2016 and December 31, 2015, respectively	395,629	327,851
Prepaid expenses and other current assets	107,810	93,622
Total current assets	594,094	538,346
Long-term marketable securities	187,500	0
Fixed assets, net	143,731	125,617
Software development costs, net	97,646	85,775
Intangible assets, net	715,701	347,646
Goodwill	1,846,944	1,222,601
Deferred taxes, net	2,488	2,298
Other assets	121,993	359,665
Total assets	3,710,097	2,681,948
Current liabilities:
Accounts payable	84,455	60,004
Accrued expenses	65,696	62,021
Accrued compensation and benefits	52,440	62,398
Deferred revenue	373,543	315,925
Current maturities of long-term debt	12,077	12,178
Non-recourse current maturities of long-term debt - Netsmart	11,602	0
Current maturities of capital lease obligations	7,509	431
Total current liabilities	607,322	512,957
Long-term debt	632,699	612,405
Non-recourse long-term debt - Netsmart	523,381	0
Long-term capital lease obligations	9,986	617
Deferred revenue	20,003	20,273
Deferred taxes, net	144,231	22,164
Other liabilities	53,966	94,459
Total liabilities	1,991,588	1,262,875
Redeemable convertible non-controlling interest - Netsmart	367,302	0
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of June 30, 2016 and December 31, 2015	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of June 30, 2016 and December 31, 2015; 267,844 and 186,556 shares issued and outstanding as of June 30, 2016, respectively; 266,545 and 189,308 shares issued and outstanding as of December 31, 2015, respectively	2,678	2,665
Treasury stock: at cost, 81,288 and 77,237 shares as of June 30, 2016 and December 31, 2015, respectively	(241,827)	(189,753)
Additional paid-in capital	1,791,838	1,789,449
Accumulated deficit	(190,235)	(190,235)
Accumulated other comprehensive loss	(22,427)	(4,242)
Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity	1,340,027	1,407,884
Non-controlling interest	11,180	11,189
Total stockholders’ equity	1,351,207	1,419,073
Total liabilities and stockholders’ equity	$ 3,710,097	$ 2,681,948

CONSOLIDATED BALANCE SHEETS (U3

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 34,649	$ 31,266
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	267,844,000	266,545,000
Common stock, shares outstanding	186,556,000	189,308,000
Treasury stock at cost, shares	81,288,000	77,237,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue:
Software delivery, support and maintenance	$ 249,871	$ 232,470	$ 479,029	$ 460,029
Client services	136,650	119,248	253,050	226,241
Total revenue	386,521	351,718	732,079	686,270
Cost of revenue:
Software delivery, support and maintenance	79,154	75,726	154,323	152,413
Client services	118,683	111,625	219,542	218,784
Amortization of software development and acquisition-related assets	22,000	20,743	39,632	41,659
Total cost of revenue	219,837	208,094	413,497	412,856
Gross profit	166,684	143,624	318,582	273,414
Selling, general and administrative expenses	94,802	86,749	178,955	168,778
Research and development	47,891	44,367	94,928	91,094
Asset impairment charges	0	293	4,650	319
Amortization of intangible and acquisition-related assets	5,417	6,624	9,579	13,327
Income (loss) from operations	18,574	5,591	30,470	(104)
Interest expense	(16,421)	(7,483)	(23,390)	(14,739)
Other income (expense), net	106	(28)	472	1,858
Equity in net (loss) earnings of unconsolidated investments	(4,898)	176	(7,501)	176
Income (loss) before income taxes	(2,639)	(1,744)	51	(12,809)
Income tax benefit (provision)	503	(1,472)	(60)	(491)
Net loss	(2,136)	(3,216)	(9)	(13,300)
Less: Net loss (income) attributable to non-controlling interest	87	(9)	9	(9)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(8,153)	0	(8,153)	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (10,202)	$ (3,225)	$ (8,153)	$ (13,309)
Loss per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.05)	$ (0.01)	$ (0.04)	$ (0.07)
Loss per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.05)	$ (0.01)	$ (0.04)	$ (0.07)

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (2,136)	$ (3,216)	$ (9)	$ (13,300)
Other comprehensive (loss) income:
Foreign currency translation adjustments	(943)	677	(199)	(391)
Change in unrealized loss on marketable securities	(18,115)	0	(18,115)	(228)
Change in fair value of derivatives qualifying as cash flow hedges	(227)	230	214	230
Other comprehensive (loss) income before income tax expense	(19,285)	907	(18,100)	(389)
Income tax benefit (expense) related to items in other comprehensive income (loss)	89	(90)	(85)	(2)
Total other comprehensive (loss) income	(19,196)	817	(18,185)	(391)
Comprehensive loss	(21,332)	(2,399)	(18,194)	(13,691)
Less: Comprehensive loss (income) attributable to non-controlling interest	87	(9)	9	(9)
Comprehensive loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (21,245)	$ (2,408)	$ (18,185)	$ (13,700)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (9)	$ (13,300)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	76,576	83,488
Stock-based compensation expense	20,057	18,317
Excess tax benefits from stock-based compensation	(962)	(333)
Deferred taxes	(1,560)	(1,059)
Asset impairment charges	4,650	319
Other losses, net	8,464	1,050
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable, net	(12,407)	11,187
Prepaid expenses and other assets	2,923	6,043
Accounts payable	15,751	(481)
Accrued expenses	(8,709)	(14,928)
Accrued compensation and benefits	(11,404)	(11,730)
Deferred revenue	37,623	10,068
Other liabilities	1,106	168
Net cash provided by operating activities	132,099	88,809
Cash flows from investing activities:
Capital expenditures	(16,632)	(9,615)
Capitalized software	(37,106)	(21,684)
Purchases of equity securities, other investments and related intangible assets	(20,685)	(210,087)
Sales and maturities of marketable securities and other investments	0	1,305
Cash paid for business acquisitions, net of cash acquired	(905,540)	(9,372)
Proceeds received from sale of fixed assets	37	15
Net cash used in investing activities	(979,926)	(249,438)
Cash flows from financing activities:
Proceeds from sale or issuance of common stock	5	101,432
Proceeds from issuance of redeemable convertible preferred stock - Netsmart	333,605	0
Excess tax benefits from stock-based compensation	962	333
Taxes paid related to net share settlement of equity awards	(7,363)	(5,533)
Payments of capital lease obligations	(1,638)	(137)
Credit facility payments	(51,362)	(41,283)
Credit facility borrowings, net of issuance costs	599,135	129,511
Repurchase of common stock	(52,075)	0
Net cash provided by financing activities	821,269	184,323
Effect of exchange rate changes on cash and cash equivalents	340	(330)
Net (decrease) increase in cash and cash equivalents	(26,218)	23,364
Cash and cash equivalents, beginning of period	116,873	53,173
Cash and cash equivalents, end of period	90,655	76,537
Supplemental non-cash information:
Exchange of Netsmart, Inc. common stock for redeemable convertible preferred stock in Netsmart by Netsmart, Inc. management	$ 25,543	$ 0

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and six months ended June 30, 2016 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the full year ending December 31, 2016. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Accounting Pronouncements Not yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic In March 2016, the FASB issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combinations	2. Business Combinations Formation of Joint Business Entity and Acquisition of Netsmart, Inc. On March 20, 2016, we entered into a Contribution and Investment Agreement (the “Contribution Agreement”) with GI Netsmart Holdings LLC, a Delaware limited liability company (“GI Partners”) to form a joint business entity, Nathan Holding LLC, a Delaware limited liability company (“Nathan”). The formation of Nathan was completed on April 19, 2016. As a result, pursuant to, and subject to the terms and conditions of, the Contribution Agreement, Nathan issued to Allscripts Class A Common Units in exchange for Allscripts contributing its Homecare TM The Nathan operating agreement provides that the Class A Preferred Units entitle the owners at any time and from time to time following the later of (A) the earlier of (I) the fifth anniversary of the effective date and (II) a change in control of Allscripts, and (B) the earlier of (I) the payment in full of the obligations under the credit facilities and the termination of any commitments thereunder or (II) with respect to any proposed redemption, such earlier date for such redemption consented to in writing by the required lenders under each of the credit facilities under which obligations remain unpaid or under which commitments continue, to redeem all or any portion of their Class A Preferred Units for cash at a price per Unit equal to the Class A Preferred liquidation preference for each such Class A Preferred Unit as of the date of such redemption. The liquidation preference is equal to the greater of (i) a return of the original issue price plus a preferred return (accruing on a daily basis at the rate of 11% per annum and compounding annually on the last day of each calendar year) or (ii) the as-converted value of Class A Common Units in Nathan. The consolidated statements of operations for the three and six months periods ended June 30, 2016, give effect to the accretion of the 11% redemption preference as part of the calculation of net income (loss) attributable to Allscripts stockholders. Also on April 19, 2016, Nathan acquired Netsmart, Inc., a Delaware corporation, pursuant to the Agreement and Plan of Merger, dated as of March 20, 2016 (the “Merger Agreement”), by and among Nathan Intermediate LLC, a Delaware limited liability company and a wholly-owned subsidiary of Nathan (“Intermediate”), Nathan Merger Co., a Delaware corporation and a wholly-owned subsidiary of Intermediate (“Merger Sub”), Netsmart, Inc. and Genstar Capital Partners V, L.P., as the equityholders’ representative. Pursuant to the Merger Agreement, on April 19, 2016, Merger Sub was merged with and into Netsmart, Inc., with Netsmart, Inc. surviving as a wholly-owned subsidiary of Intermediate (the “Merger”). As a result of these transactions (the “Netsmart Transaction” or “Netsmart Acquisition”), the establishment of Nathan combined the Allscripts Homecare TM At the effective time of the Merger, Netsmart, Inc.’s common stock shares issued and outstanding immediately prior to the effective time were converted into the right to receive a pro rata share of $950 million, reduced by net debt and subject to working capital and other adjustments (the “Purchase Price”). Each vested outstanding option to acquire shares of Netsmart, Inc.’s common stock became entitled to receive a pro rata share of the Purchase Price, less applicable exercise prices of the options. Certain holders of shares of Netsmart, Inc.’s common stock, who were members of Netsmart, Inc.’s management, exchanged a portion of such shares for equity interests in Nathan, in lieu of receiving their pro rata share of the Purchase Price, and certain holders of options to purchase Netsmart, Inc.’s common stock, who were also members of Netsmart, Inc.’s management, invested a portion of such holder’s proceeds from the Merger in equity interests in Nathan (collectively, the “Rollover”). After the completion of the Merger and the Rollover, Allscripts owned 49.1%, GI Partners owned 47.2% and Netsmart’s management owned 3.7% of the outstanding equity interests in Netsmart, in each case on an as-converted basis. As part of the Netsmart Transaction, we deposited $15 million in an escrow account to be used by Netsmart to facilitate the integration of our Homecare TM Pursuant to the consolidation guidance in FASB Accounting Standards Codification (“ASC”) Topic 810, Consolidation, we performed a qualitative and quantitative assessment to determine whether Netsmart was a variable interest entity (“VIE”). Our assessment involved consideration of all facts and circumstances relevant to the Netsmart’s structure, including its capital structure, contractual rights to earnings (losses), subordination of our interests relative to those of other investors, contingent payments, as well as other contractual arrangements that have potential to be economically significant. Based on this analysis, we determined that Netsmart was not a VIE and that we, through our 49.1% interest in Netsmart and other contractual rights including budgetary approval, have the power to direct the activities of Netsmart that most significantly impact its economic performance. As a result, we concluded that we will account for our investment in Netsmart on a consolidated basis and the financial results of Netsmart will be consolidated with Allscripts’ starting on April 19, 2016. The acquisition of Netsmart, Inc. by Nathan was completed for an aggregate Purchase Price of $937 million. The Purchase Price was funded by the sources of funds as described in the table below. The Netsmart term loans are non-recourse to Allscripts and its wholly-owned subsidiaries. A portion of the debt proceeds were used to extinguish Netsmart, Inc.’s existing debt of $325 million, including accrued interest and fees of $2 million. The sources of funds used in connection with the Netsmart Acquisition are as follows: (In thousands) Cash contribution for redeemable convertible non-controlling interest in Netsmart - GI Partners $ 333,606 Exchange of Netsmart, Inc.'s common stock for redeemable convertible non-controlling interest in Netsmart - Netsmart, Inc. management 25,543 Cash contribution from borrowings under revolver in exchange for common stock in Netsmart - Allscripts 43,782 Net borrowings under new term loans - Netsmart 534,135 Total funds used for the acquisition $ 937,066 Under the acquisition method of accounting, the fair value of consideration transferred for Netsmart, Inc. was allocated to the tangible and intangible assets acquired and the liabilities assumed based on their estimated fair values as of the acquisition date with the remaining unallocated amount recorded as goodwill. (In thousands) Cash and cash equivalents $ 5,982 Accounts receivable, net 54,510 Prepaid expenses and other current assets 9,266 Fixed assets 26,829 Intangible assets 397,500 Goodwill 625,273 Other assets 6,542 Accounts payable (14,151 ) Accrued expenses (11,690 ) Deferred revenue (18,843 ) Capital lease obligations (17,833 ) Deferred taxes, net (122,646 ) Other liabilities (3,673 ) Net assets acquired $ 937,066 Allscripts’ contribution of its Homecare TM As noted above, the formation of Netsmart resulted in the merger of our Homecare TM The acquired intangible assets are being amortized over their useful lives, using a method that approximates the pattern of economic benefits to be gained by the intangible asset and consist of the following amounts for each class of acquired intangible asset: (Dollar amounts in thousands) Useful Life Description in Years Fair Value Technology 10-12 yrs $ 143,000 Corporate Trademark indefinite 27,000 Product Trademarks 10 yrs 8,500 Customer Relationships 12-20 yrs 219,000 $ 397,500 Acquisition costs related to the Netsmart acquisition are included in selling, general and administrative expenses in the accompanying consolidated statement of operations and totaled $0.4 million and $4.1 million for the three and six months ended June 30, 2016, respectively. The revenue and net loss of Netsmart since April 19, 2016 are included in our consolidated statement of operations for the three months ended June 30, 2016 and the supplemental pro forma revenue and net loss of the combined entity, presented as if the acquisition of Netsmart, Inc. had occurred on January 1, 2015, are as follows: Three Months Ended June 30, Six Months Ended June 30, (In thousands, except per share amounts) 2016 2015 2016 2015 Actual from Netsmart since acquisition date of April 19, 2016: Revenue $ 44,233 $ 0 $ 44,233 $ 0 Net loss $ (7,113 ) $ 0 $ (7,113 ) $ 0 Supplemental pro forma data for combined entity: Revenue $ 403,388 $ 391,238 $ 798,395 $ 756,268 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (45,442 ) $ (23,602 ) $ (61,202 ) $ (67,036 ) Loss per share, basic and diluted $ (0.24 ) $ (0.13 ) $ (0.33 ) $ (0.37 ) The supplemental pro forma results were calculated after applying our accounting policies and adjusting the results of Netsmart to reflect (i) the additional depreciation and amortization that would have been charged resulting from the fair value adjustments to property, plant and equipment and intangible assets, (ii) the additional interest expense associated with Netsmart’s borrowings under the new term loans, and (iii) the additional amortization of the estimated adjustment to decrease the assumed deferred revenue obligations to fair value that would have been charged assuming the acquisition occurred on January 1, 2015, together with the consequential tax effects. Supplemental pro forma results for the three and six months ended June 30, 2016 were also adjusted to exclude acquisition-related and transaction costs incurred during these periods. Supplemental pro forma results for the three and six months ended June 30, 2015 were adjusted to include these items. The supplemental pro forma results for the three and six months ended June 30, 2016 include $48.6 million of expenses incurred by Netsmart immediately prior to the Netsmart Transaction related to the pay-out of outstanding equity awards and the payment of seller costs. The effects of transactions between us and Netsmart during the periods presented have been eliminated.

Fair Value Measurements and Inv

Fair Value Measurements and Investments	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements and Investments	3. Fair Value Measurements and Investments We carry a portion of our financial assets and liabilities at fair value that are measured at a reporting date using an exit price (i.e., the price that would be received to sell an asset or paid to transfer a liability) and disclosed according to the quality of valuation inputs under the following hierarchy: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Level 3: Unobservable inputs that are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability that are not actively traded. These derivative instruments were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for these instruments is substantially mitigated. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet June 30, 2016 December 31, 2015 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 1.25% Call Option Other assets $ 0 $ 0 $ 38,498 $ 38,498 $ 0 $ 0 $ 80,208 $ 80,208 NantHealth Common Stock Long-term marketable securities 187,500 0 0 187,500 0 0 0 0 1.25% Embedded cash conversion option Other liabilities 0 0 (39,240 ) (39,240 ) 0 0 (81,210 ) (81,210 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 638 0 638 0 424 0 424 Foreign exchange derivative liabilities Accrued expenses 0 0 0 0 0 0 0 0 Total $ 187,500 $ 638 $ (742 ) $ 187,396 $ 0 $ 424 $ (1,002 ) $ (578 ) Investments The following table summarizes our equity investments which are included in other assets in the accompanying consolidated balance sheet: Number of Original Carrying Value at (In thousands) Investees Investment June 30, 2016 December 31, 2015 Equity method investments (1): Nant Health, LLC (2) 0 0 0 203,117 Other 3 1,658 2,436 2,436 Total equity method investments 3 1,658 2,436 205,553 Cost method investments 5 29,991 26,041 17,876 Total equity investments 8 $ 31,649 $ 28,477 $ 223,429 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. (2) As noted below, effective June 2, 2016, Nant Health LLC is no longer accounted for under the equity method. Effective June 1, 2016, in preparation for an initial public offering (“IPO”) of its equity securities, Nant Health converted from an LLC into a Delaware corporation under the name of NantHealth, Inc. (“NantHealth”). We received 14,285,714 shares of common stock in the new corporation in replacement of our Series G Units of the former Nant Health LLC, representing a 12.6% ownership interest in NantHealth immediately prior to the IPO. On June 2, 2016, NantHealth completed its IPO offering of 6,500,000 shares and its stock began trading on the NASDAQ under the ticker symbol “NH”. The issuance of the IPO shares initially diluted our ownership interest to 11.8%. Also on June 2, 2016, we purchased an additional 714,286 shares at the IPO price of $14 per share for an additional investment in NantHealth of $10 million. This additional share purchase brought our total voting interest in NantHealth to 15,000,000 shares or 12.4% of the voting common stock. Based on the guidance under FASB ASC Topic 323, Investments – Equity Method and Joint Ventures In accordance with FASB ASC Topic 320, Investments – Debt and Equity Securities Fair Value Measurement The decline in the carrying value of our equity method investments from December 31, 2015 to June 30, 2016 was primarily due to NantHealth no longer being accounted for under the equity method as discussed above. The increase in the carrying value of our cost method investments from December 31, 2015 to June 30, 2016 was due to the acquisition of two additional non-marketable equity securities during the second quarter of 2016, as discussed below. This was offset by the recognition of an impairment charge of $2.1 million on one investment during the first quarter of 2016. During first quarter of 2016, we acquired a $0.5 million non-marketable convertible note of a third party with which we have an existing license and distribution agreement. This investment is accounted as an available-for-sale security with changes in fair value recorded in accumulated other comprehensive loss. The fair value of the convertible note was $0.5 million as of June 30, 2016 and was included in other assets in the accompanying consolidated balance sheet as of June 30, 2016. During second quarter of 2016, we acquired certain non-marketable equity securities of two third parties and entered into new commercial agreements with each of those third parties to license and distribute their products and services, for a total consideration of approximately $10.2 million. Both of these equity investments acquired during the second quarter are accounted for under the cost method. The carrying value of these investments was approximately $10.2 million as of June 30, 2016 and are included in other assets in the accompanying consolidated balance sheet. As of June 30, 2016, i . Summarized Financial Information for Equity Method Investments Summarized financial information for our equity method investments on an aggregated basis since the date of acquisition is as follows: March 31, December 31, (In thousands) 2016 2015 Current assets $ 69,491 $ 42,239 Noncurrent assets 571,076 397,519 Current liabilities 214,690 52,482 Noncurrent liabilities 45,920 191,563 Equity of equity method investments $ 379,957 $ 195,713 (In thousands) Trailing Three Months Ended March 31, 2016 Trailing Three Months Ended March 31, 2015 Trailing Six Months Ended March 31, 2016 Trailing Six Months Ended March 31, 2015 Revenue $ 28,557 $ 3,019 $ 51,893 $ 5,729 Net loss (35,385 ) 234 (59,925 ) 18 Long-Term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility and Netsmart’s Credit Agreements (as defined in Note 8, Debt), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as of June 30, 2016, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 8, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Shareholders' Equity	4. Stockholders' Equity Stock-based Compensation Expense Stock-based compensation expense recognized during the three and six months ended June 30, 2016 and 2015 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. In addition, the table below includes stock-based compensation expense related to Netsmart’s time-based liability classified option awards. No stock-based compensation costs were capitalized during the three and six months ended June 30, 2016 and 2015. Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Cost of revenue: Software delivery, support and maintenance $ 1,061 $ 1,179 $ 2,230 $ 2,275 Client services 1,138 1,322 2,628 2,730 Total cost of revenue 2,199 2,501 4,858 5,005 Selling, general and administrative expenses 6,342 5,200 11,508 10,211 Research and development 2,119 2,317 4,695 4,320 Total stock-based compensation expense $ 10,660 $ 10,018 $ 21,061 $ 19,536 Allscripts Stock-based Awards We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based restricted stock units and restricted stock awards is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three and six months ended June 30, 2016 and 2015. We granted stock-based awards as follows: Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 193 $ 13.26 1,995 $ 13.14 Performance-based restricted stock units with a service condition 0 $ 0.00 545 $ 12.39 Market-based restricted stock units with a service condition 0 $ 0.00 621 $ 13.49 193 $ 13.26 3,161 $ 13.08 During the six months ended June 30, 2016 and the year ended December 31, 2015, 1.3 million and 1.4 million shares of stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards. Net Share-settlements Beginning in 2011, upon vesting, restricted stock units and awards are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested in 2016 and 2015 were net-share settled such that we withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the six months ended June 30, 2016 and 2015 were 564 thousand and 422 thousand, respectively, and were based on the value of the restricted stock units and awards on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Stock Repurchases In November 2015, our Board of Directors authorized a stock repurchase program under which we may repurchase up to $150 million of our common stock through December 31, 2018. Any share repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time. During the three and six months ended June 30, 2016, we repurchased 1.2 million and 4.1 million shares, respectively, of our common stock for $14.5 million and $52.0 million, respectively, pursuant to this stock repurchase program. As of June 30, 2016, the amount available for repurchase of common stock under this program was $98.0 million. Issuance of Warrants On June 30, 2016, we issued to a commercial partner, as part of an overall commercial relationship, unregistered warrants to purchase 900,000 shares of Company common stock, par value $0.01 per share at a price per share of $12.47, 1,000,000 shares of common Stock at a price per share of $14.34, and 1,100,000 shares of common Stock at a price per share of $15.59, in each case subject to customary anti-dilution adjustments. The warrants vest in four equal annual installments of 750 thousand shares beginning in June 2017 and expire in June 2026. Our issuance of the warrants was a private placement exempt from registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. Netsmart Long-Term Incentive Plan Netsmart has established the Nathan Holding LLC 2016 Unit Option Plan (the “Plan”) in order to provide key employees, managers, advisors and consultants of Netsmart and its affiliates with an opportunity to acquire an equity interest in Netsmart. The Plan provides for the maximum issuance of 116,491 thousand options related to Netsmart’s Class B Non-Voting Common Member Units (“Option Units”). The option unit grants may contain varying vesting conditions, including service, performance and market conditions established on a grant‑by‑grant basis as determined by the compensation committee of the board of directors and expire no more than 10 years after the date of grant. The Plan includes a call right which enables Netsmart to repurchase any outstanding units in the event of termination of employment. At June 30, 2016, there were 28,502 thousand Class B Non-Voting Common Units available for further issuance under the Plan. For the period from April 19 th Time Based During the period from April 19, 2016 through June 30, 2016, Netsmart granted 62,849 thousand Option Units, to certain of its executives and employees. The Option Units were granted with an exercise price of $1.00 per Option Unit. The Option Units vest ratably over a period of four years, with the first twenty-five percent vesting at the first anniversary of the issuance and the remaining vesting in equal monthly increments over the following thirty-six months. The Option Units are liability‑classified awards requiring the Option Units to be re‑measured at fair value at each reporting period. Performance Based During the period from April 19 th A summary of the activity under the Plan is as follows: (Units in thousands) Option Units Weighted Average Exercise Price Granted during the period 87,989 $ 1.00 Options called during the period 0 $ 0.00 Options exercised during the period 0 $ 0.00 Forfeited during the period 0 $ 0.00 Outstanding – June 30, 2016 87,989 $ 1.00 Exercisable – June 30, 2016 0 $ 0.00 Option Units outstanding at June 30, 2016 are as follows: (Units in thousands) Outstanding Exercisable Exercise price Units Average Black-Scholes Value Weighted Average Remaining Life Shares Average Black-Scholes Value Weighted Average Remaining Life $ 1.00 87,989 $ 0.46 7.00 0 $ 0.00 0 As the current estimated fair value equals the exercise price of the Option Units as of June 30, 2016, there was no intrinsic value related to the outstanding Option Units. The compensation expense was included in the following categories in Netsmart’s statements of operations: (in thousands) June 30, 2016 Cost of sales $ 62 Research and development 36 Sales and marketing 93 General and administrative 1,235 Total $ 1,426 At June 30, 2016 the liability for outstanding awards was $1.4 The fair value of Option Units granted during the period from April 19, 2016 through June 30, 2016 was estimated using the Black‑Scholes‑Merton option pricing model using the following weighted average assumptions: Average expected term in years 7.0 Risk free rate (weighted average) 1.3 % Expected dividends 0.0 % Average volatility 43.4 % Netsmart determined the estimated share price of $1.00 at June 30 , The expected term of the awards was determined based upon an estimate of the expected term of “plain vanilla” options as prescribed by the simplified method. The risk‑free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Netsmart estimates expected volatility based primarily on historical monthly volatility of comparable companies that are publicly traded. Netsmart has $27.5 million of share‑based compensation expense remaining to be recognized (based on the June 30, 2016 fair value) over future periods as follows: $3.6 million in 2016, $7.2 million in 2017, $7.2 million in 2018, $7.2 million in 2019, and $2.3 million in 2020.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	5. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Three Months Ended June 30, Six Months Ended June 30, (In thousands, except per share amounts) 2016 2015 2016 2015 Basic Loss per Common Share: Net loss $ (2,136 ) $ (3,216 ) $ (9 ) $ (13,300 ) Less: Net loss (income) attributable to non-controlling interest $ 87 $ (9 ) $ 9 $ (9 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest $ (8,153 ) $ 0 $ (8,153 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (10,202 ) $ (3,225 ) $ (8,153 ) $ (13,309 ) Weighted-average common shares outstanding 186,792 181,558 187,676 181,072 Basic Loss per Common Share $ (0.05 ) $ (0.01 ) $ (0.04 ) $ (0.07 ) Diluted Loss per Common Share: Net loss $ (2,136 ) $ (3,216 ) $ (9 ) $ (13,300 ) Less: Net loss (income) attributable to non-controlling interest $ 87 $ (9 ) $ 9 $ (9 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest $ (8,153 ) $ 0 $ (8,153 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (10,202 ) $ (3,225 ) $ (8,153 ) $ (13,309 ) Weighted-average common shares outstanding 186,792 181,558 187,676 181,072 Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 0 Weighted-average common shares outstanding assuming dilution 186,792 181,558 187,676 181,072 Diluted Loss per Common Share $ (0.05 ) $ (0.01 ) $ (0.04 ) $ (0.07 ) As a result of the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three and six months ended June 30, 2016 and 2015, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for that period, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 25,210 23,759 25,227 23,351

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: June 30, 2016 December 31, 2015 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 593,383 $ (321,221 ) $ 272,162 $ 450,852 $ (302,284 ) $ 148,568 Customer contracts and relationships 779,326 (414,787 ) 364,539 552,395 (405,317 ) 147,078 Total $ 1,372,709 $ (736,008 ) $ 636,701 $ 1,003,247 $ (707,601 ) $ 295,646 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 52,000 Goodwill 1,846,944 1,222,601 Total $ 1,925,944 $ 1,274,601 Effective January 1, 2016, we made an organizational change within our Clinical and Financial Solutions reportable segment. Refer to Note 13, “Business Segments” for additional information. As a result of this organizational change, we assessed our revised reporting units and allocated the goodwill previously assigned to our former Touchworks reporting unit to our new Acute and Ambulatory reporting units based on the relative fair value allocation method as applied to the separate Touchworks acute and ambulatory businesses. During the three months ended June 30, 2016 we completed the Netsmart Transaction and recorded additional goodwill and intangible assets relating the acquisition of Netsmart, Inc. As noted above, the formation of Netsmart resulted in the merger of our Homecare TM TM TM We performed our annual goodwill impairment test as of October 1, 2015, our annual testing date, and again as of January 1, 2016 in conjunction with the organizational change within our Clinical and Financial Solutions reportable segment and March 31, 2016 in conjunction with the Netsmart Transaction and related carve-out of our Homecare TM TM TM TM TM Changes in the carrying amounts of goodwill by reportable segment for the six months ended June 30, 2016 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2015 $ 796,367 $ 426,234 $ 0 $ 1,222,601 Acquisition 0 0 625,273 625,273 Reallocation 0 (37,600 ) 37,600 0 Foreign exchange translation (930 ) 0 0 (930 ) Balance as of June 30, 2016 $ 795,437 $ 388,634 $ 662,873 $ 1,846,944 The acquisition of goodwill during the six months ended June 30, 2016 relates to goodwill arising from our acquisition of Netsmart during the three months ended June 30, 2016. The goodwill reallocation during the six months ended June 30, 2016 relates to the allocation of goodwill associated with our Homecare TM There were no accumulated impairment losses associated with our goodwill as of June 30, 2016 or December 31, 2015.

Asset Impairment Charges

Asset Impairment Charges	6 Months Ended
	Jun. 30, 2016
Asset Impairment Charges [Abstract]
Asset Impairment Charges	7. Asset Impairment Charges We incurred the following impairment charges: Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 (In thousands) 2016 2015 2016 2015 Asset impairment charges $ 0 $ 293 $ 4,650 $ 319 During the six months ended June 30, 2016, we incurred non-cash asset impairment charges totaling $4.7 million, all of which were incurred in the first quarter of 2016. Included in these charges was $2.2 million for the impairment of capitalized software as a result of our decision to discontinue several software development projects, $2.1 million for the impairment of one of our cost method equity investments, and other charges of $0.4 million to write down a long-term asset to its estimated net realizable value. Asset impairment charges for the first half of 2015 were not significant.

Debt

Debt	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Debt	8. Debt Debt outstanding, excluding capital leases, consisted of the following: June 30, 2016 December 31, 2015 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 55,554 $ 289,446 $ 345,000 $ 61,771 $ 283,229 Senior Secured Credit Facility 360,625 5,366 355,259 346,875 5,704 341,171 Netsmart Non-Recourse Debt: First Lien Term Loan 395,000 17,319 377,681 0 0 0 Second Lien Term Loan 167,000 9,698 157,302 0 0 0 Other debt 71 0 71 183 0 183 Total debt $ 1,267,696 $ 87,937 $ 1,179,759 $ 692,058 $ 67,475 $ 624,583 Less debt payable within one year 12,570 493 12,077 12,657 479 12,178 Less debt payable within one year - Netsmart 15,800 4,198 11,602 0 0 0 Total long-term debt, less current maturities $ 1,239,326 $ 83,246 $ 1,156,080 $ 679,401 $ 66,996 $ 612,405 Interest expense consisted of the following: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Interest expense $ 3,595 $ 4,008 $ 7,133 $ 7,869 Amortization of discounts and debt issuance costs 3,448 3,418 6,879 6,813 Write off of unamortized deferred debt issuance costs 0 57 0 57 Netsmart: Interest expense (1) 8,530 0 8,530 0 Amortization of discounts and debt issuance costs 848 0 848 0 Total interest expense $ 16,421 $ 7,483 $ 23,390 $ 14,739 (1) Includes interest expense related to capital leases. Interest expense related to the 1.25% Notes was comprised of the following: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Coupon interest at 1.25% $ 1,078 $ 1,078 $ 2,156 $ 2,156 Amortization of discounts and debt issuance costs 3,108 2,977 6,216 5,925 Total interest expense related to the 1.25% Notes $ 4,186 $ 4,055 $ 8,372 $ 8,081 Allscripts Senior Secured Facility As of June 30, 2016, $240.6 million under a term loan, $120.0 million under our revolving credit facility, and $0.8 million in letters of credit were outstanding under our senior secured credit facility. As of June 30, 2016, the interest rate on the United States dollars-denominated borrowings under our senior secured credit facility was LIBOR plus 1.75%, which totaled 2.21%. We were in compliance with all covenants under the senior secured credit facility agreement as of June 30, 2016. As of June 30, 2016, we had $429.2 million available, net of outstanding letters of credit, under our revolving credit facility. There can be no assurance that we will be able to draw on the full available balance of our revolving credit facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. As of June 30, 2016, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount. Netsmart Non-Recourse Debt On April 19, 2016, Netsmart entered into a First and Second Lien Credit Agreement (the “Netsmart First Lien Credit Agreement” and the “Netsmart Second Lien Credit Agreement”, respectively), with a syndicate of financial institutions and UBS AG, Stamford Branch, as administrative agent. The Netsmart First Lien Credit Agreement provides for a $395 million senior secured 7-year term loan credit facility (the “Netsmart First Lien Term Loan”) and a $50 million senior secured 5-year revolving loan credit facility (the “Netsmart Revolving Facility”). The Netsmart Second Lien Credit Agreement provides for a $167 million senior secured 7.5-year term loan credit facility (the “Netsmart Second Lien Term Loan,” and, together with the Netsmart First Lien Credit Agreement, the “Netsmart Credit Agreements”). Each of Netsmart’s obligations under the Netsmart Credit Agreements are guaranteed by Intermediate, each other Borrower, each Subsidiary Guarantor and any other person who becomes a party to the Netsmart Credit Agreements, under an unconditional guaranty. Netsmart’s debt under the Netsmart Credit Agreements is non-recourse to Allscripts and its wholly-owned subsidiaries. The Netsmart Revolving Facility will terminate on April 19, 2021 and Netsmart First Lien Term Loan matures on April 19, 2023. The Netsmart Second Lien Term Loan matures on October 19, 2023. All unpaid principal of, and interest accrued on, such loans must be repaid on their respective maturity dates. The outstanding principal amount of the Netsmart Term Loans and the Netsmart Revolving Facility bear interest at a rate equal to (a) with respect to LIBO Rate Loans, Adjusted LIBO Rate plus 4.75% and (b) with respect to ABR Loans, 3.75% (provided, however, that in respect of the Netsmart Revolving Loans, such rate may step-down to 4.25% and 3.25%, respectively, depending on the then-applicable leverage ratio) and (b) of the Netsmart Second Lien Term Loans bear interest at a rate equal to (a) with respect to LIBO Rate Loans, Adjusted LIBO Rate plus 9.50% and (b) with respect to ABR Loans, 8.50%. The proceeds from the funding of the Netsmart Credit Agreements were used to, inter alia The Netsmart Credit Agreements contain a financial covenant that Intermediate and its subsidiaries maintain a maximum ratio of total debt to Consolidated Adjusted EBITDA. The entire principal amount of the Netsmart Credit Agreements and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs. Events of default under the Netsmart Credit Agreements include (but are not limited to) failure to make payments when due, a default in the performance of any covenants in the Netsmart Credit Agreements or related documents or certain changes of control of Intermediate and/or of Netsmart. The Netsmart First Lien Credit Agreement Netsmart Second Lien Credit Agreement In connection with the Netsmart Credit Agreements, during the three months ended June 30, 2016, Netsmart incurred fees and other costs totaling approximately $27.9 million which were capitalized and included in the net borrowings outstanding under Netsmart’s Credit Agreements as of June 30, 2016. As of June 30, 2016, $395.0 million under the Netsmart First Lien Term Loan, $167.0 million under the Netsmart Second Lien Term Loan and $1.5 million in letters of credit under the Netsmart Revolving Facility were outstanding. As of June 30, 2016, the interest rate on the borrowings under the Netsmart First Lien Term Loan and the Netsmart Revolving Facility was Adjusted LIBO plus 4.75%, which totaled 5.75%. As of June 30, 2016, the interest rate on the borrowings under the Netsmart Second Lien Term Loan was Adjusted LIBO plus 9.5%, which totaled 10.5%. Netsmart was in compliance with all covenants under its Credit Agreements as of June 30, 2016. As of June 30, 2016, Netsmart had $48.5 million available, net of outstanding letters of credit, under the Netsmart Revolving Facility. There can be no assurance that Netsmart will be able to draw on the full available balance of the Netsmart Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. The following table summarizes our future payment obligations under our debt as of June 30, 2016: (In thousands) Total Remainder of 2016 2017 2018 2019 2020 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 0 $ 345,000 $ 0 Term Loan 240,625 6,250 15,625 28,125 40,625 150,000 0 Revolving Facility 120,000 0 0 0 0 120,000 0 Netsmart Non-Recourse Debt: First Lien Term Loan 395,000 7,900 15,800 15,800 15,800 15,800 323,900 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Other debt 71 71 0 0 0 0 0 Total debt $ 1,267,696 $ 14,221 $ 31,425 $ 43,925 $ 56,425 $ 630,800 $ 490,900 (1)

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes We account for income taxes under FASB Accounting Standards Codification 740, Income Taxes Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Income (loss) before income taxes $ (2,639 ) $ (1,744 ) $ 51 $ (12,809 ) Income tax benefit (provision) $ 503 $ (1,472 ) $ (60 ) $ (491 ) Effective tax rate 19.1 % (84.4 %) 117.6 % (3.8 %) Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance, permanent differences, income attributable to foreign jurisdictions taxed at lower rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three months ended June 30, 2016, compared with the prior year comparable period, differs primarily due to the fact that t he income tax (provision) benefit for the three months ended June 30, 2015 did not include any tax benefit for year to date losses due to our estimate of income at that time for overall annual results of operation for 2015. Additionally, no estimate of the research and development credit was included in the effective tax rate for the three and six months ended June 30, 2015 as the credit had not been reinstated for 2015 until December 18, 2015. Lastly, the effective tax rate for the three and six months ended June 30, 2016, was impacted by the In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). Because of the near break-even pre-tax income for the six months ended June 30, 2016, no valuation allowance has been released in the six months ended June 30, 2016. Our unrecognized income tax benefits were $13.1 million and $11.8 million as of June 30, 2016 and December 31, 2015, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	10. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: June 30, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 638 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 38,498 N/A 1.25% Embedded cash conversion option N/A Other liabilities 39,240 Total derivatives $ 39,136 $ 39,240 December 31, 2015 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 424 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 80,208 N/A 1.25% Embedded cash conversion option N/A Other liabilities 81,210 Total derivatives $ 80,632 $ 81,210 N/A – We define “N/A” as disclosure not being applicable Foreign Exchange Contracts Starting in 2015, we entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of June 30, 2016, there were 24 forward contracts outstanding that were staggered to mature monthly starting in July 2016 and ending in December 2017. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond December 2017. As of June 30, 2016, the notional amounts of outstanding forward contracts ranged from 20 million to 140 million INR, or the equivalent of $0.3 million to $2.1 million, based on the exchange rate between the United States dollar and the INR in effect as of June 30, 2016. These amounts also approximate the ranges of forecasted future INR expenses we target to hedge in any one month in the future. The critical terms of the forward contracts and the related hedged forecasted future expenses matched and allowed us to designate the forward contracts as highly effective cash flow hedges. The effective portion of the change in fair value is initially recorded in accumulated other comprehensive loss (“AOCI”) and subsequently reclassified to income in the period in which the cash flows from the associated hedged transactions affect income. Any ineffective portion of the change in fair value of the cash flow hedges is recognized in current period income. During the three and six months ended June 30, 2016, no amount was excluded from the effectiveness assessment and no gains or losses were reclassified from AOCI into income as a result of forecasted transactions that failed to occur. As of June 30, 2016, we estimate that $0.5 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months. The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Foreign exchange contracts $ (141 ) $ 201 Cost of Revenue $ 27 $ (4 ) Selling, general and administrative expenses 22 (3 ) Research and development 37 (6 ) Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Foreign exchange contracts $ 230 $ 230 Cost of Revenue $ 0 $ 0 Selling, general and administrative expenses 0 0 Research and development 0 0 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to the cash settlement features until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 3, “Fair Value Measurements and Investments.” The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 3, “Fair Value Measurements and Investments.” The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes embedded cash conversion option in the consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 1.25% Call Option $ (10,507 ) $ 17,064 $ (41,710 ) $ 9,855 1.25% Embedded cash conversion option 10,577 (17,248 ) 41,970 (10,014 ) Net gain (loss) included in other income, net $ 70 $ (184 ) $ 260 $ (159 )

Other Comprehensive Income

Other Comprehensive Income	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Other Comprehensive Income	11. Other Comprehensive Income Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Marketable Securities (3) Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive (loss) income before reclassifications (199 ) (18,115 ) 121 (18,193 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 8 8 Net other comprehensive (loss) income (199 ) (18,115 ) 129 (18,185 ) Balance as of June 30, 2016 (2) $ (4,699 ) $ (18,115 ) $ 387 $ (22,427 ) (1) (2) (3) Marketable securities represent NantHealth common stock (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Marketable Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2014 (1) $ (2,119 ) $ 140 $ 0 $ (1,979 ) Other comprehensive (loss) income before reclassifications (391 ) 0 140 (251 ) Net gains reclassified from accumulated other comprehensive loss 0 (140 ) 0 (140 ) Net other comprehensive (loss) income (391 ) (140 ) 140 (391 ) Balance as of June 30, 2015 (2) $ (2,510 ) $ 0 $ 140 $ (2,370 ) (1) (2) Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended June 30, 2016 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (943 ) $ 0 $ (943 ) $ 677 $ 0 $ 677 Marketable securities: Net loss arising during the period (18,115 ) 0 (18,115 ) 0 0 0 Net gain reclassified into income 0 0 0 0 0 0 Net change in unrealized losses on marketable securities (18,115 ) 0 (18,115 ) 0 0 0 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period (141 ) 55 (86 ) 230 (90 ) 140 Net (gains) losses reclassified into income (86 ) 34 (52 ) 0 0 0 Net change in unrealized (losses) gains on foreign exchange contracts (227 ) 89 (138 ) 230 (90 ) 140 Net (loss) gain on cash flow hedges (227 ) 89 (138 ) 230 (90 ) 140 Other comprehensive (loss) income $ (19,285 ) $ 89 $ (19,196 ) $ 907 $ (90 ) $ 817 Six Months Ended June 30, 2016 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (199 ) $ 0 $ (199 ) $ (391 ) $ 0 $ (391 ) Marketable securities: Net loss arising during the period (18,115 ) 0 (18,115 ) 0 0 0 Net (gain) loss reclassified into income 0 0 0 (228 ) 88 (140 ) Net change in unrealized (losses) gains on marketable securities (18,115 ) 0 (18,115 ) (228 ) 88 (140 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 201 (80 ) 121 230 (90 ) 140 Net (gains) losses reclassified into income 13 (5 ) 8 0 0 0 Net change in unrealized gains (losses) on foreign exchange contracts 214 (85 ) 129 230 (90 ) 140 Net gain (loss) on cash flow hedges 214 (85 ) 129 230 (90 ) 140 Other comprehensive loss $ (18,100 ) $ (85 ) $ (18,185 ) $ (389 ) $ (2 ) $ (391 )

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Contingencies	12. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated, certain of which are discussed below. We intend to vigorously defend ourselves in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. If one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients, which could further adversely affect our operating results. In the opinion of our management, based on the information currently available, there was not at least a reasonable possibility that we may have incurred any material loss, or any material loss in excess of a recorded accrual, with respect to the following matters. Our management will continue to evaluate the potential exposure related to these matters in future periods. On September 14, 2010, Pegasus Imaging Corporation filed a complaint against us in the Circuit Court of the Thirteenth Judicial Circuit of the State of Florida in and for Hillsborough County, Florida, which we transferred to the Special Superior Court for Complex Business Cases. The lawsuit also named former officers Jeffrey Amrein and John Reinhart as defendants. The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations, and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud, and negligence. On June 27, 2013, we filed our First Amended Answer, Defenses, and Counterclaims to the plaintiff’s Second Amended Complaint, denying all material allegations, and asserting counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation. On July 7, 2014, the Court granted our motion for summary judgment on the plaintiff’s claim of unfair trade practices under Florida law and our motion for summary judgment as to the aforementioned defunct corporations, and granted the plaintiff’s motion for summary judgment on our counterclaims, for which the plaintiff has moved for reconsideration. Trial has been scheduled for February 2017, and we will participate in court-ordered mediation prior to trial. On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in U.S. District Court for the Northern District of Illinois against us. The complaint alleges that on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff seeks $500 for each alleged violation of the TCPA; treble damages if the Court finds the violations to be willful, knowing or intentional; and injunctive and other relief. Allscripts answered the complaint denying all material allegations and asserting a number of affirmative defenses, as well as counterclaims for breach of a license agreement. After plaintiff’s motion to compel arbitration of the counterclaims was granted, Allscripts made a demand in arbitration where the counterclaims remain pending. Discovery in the proposed class action has now concluded. On March 31, 2016, plaintiff filed its motion for class certification.

Business Segments

Business Segments	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Business Segments	13. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as, outsourcing, remote hosting and revenue cycle management. In an effort to further streamline and align our operating structure around our key ambulatory and acute products, effective January 1, 2016, we made changes to our organizational and reporting structure. These changes included (i) the separation of the former Touchworks strategic business unit and its dedicated leadership team into acute and ambulatory businesses, and (ii) the transfer of several ancillary analytics-type products between our existing Clinical and Financial Solutions and Population Health reportable segments. In conjunction with these changes, we formed new Ambulatory and Acute strategic business units, which are deemed to be operating segments within the Clinical and Financial Solutions reportable segment. The ancillary products are extensions of our key ambulatory and acute solutions and in the future will be managed within the new Ambulatory and Acute strategic business units. The prior period segment disclosures below were revised to conform to the current year presentation. Effective on April 19, 2016 we completed the Netsmart Transaction which resulted in the formation of Netsmart through the merger of our Homecare TM TM TM Segment Reporting After the finalization of the above changes to our organizational and reporting structure, as of June 30, 2016, we had five operating segments which are aggregated into three reportable segments. The Clinical and Financial Solutions reportable segment includes the new Ambulatory and Acute, and the Payer and Life Sciences strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical software applications and financial and information solutions, which primarily include Electronic Health Record-related software, financial and practice management software, related installation, support and maintenance, outsourcing, hosting, revenue cycle management, training and electronic claims administration services. The Population Health reportable segment is comprised of a single strategic business unit, which represents a separate operating segment, and derives its revenue from the sale of health management and coordinated care solutions, which are mainly targeted at hospitals, health systems, other care facilities and Accountable Care Organizations. These solutions enable clients to connect, transition, analyze, and coordinate care across the entire care community. The Netsmart reportable segment is comprised of the Netsmart strategic business unit, which represents a separate operating segment. Netsmart operates in the behavioral healthcare information technology field throughout the United States and provides software and technology solutions to the health and human services industry, which comprises behavioral health, addiction treatment, intellectual and developmental disability services, and child and family services. Our CODM uses segment revenues, gross profit and income from operations as measures of performance and to allocate resources. With the exception of the Netsmart segment, in determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. With the exception of the Netsmart segment, we also exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting, and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed, as well as revenue and the associated cost from the resale of certain ancillary products, primarily hardware, other than the respective amounts associated with the Netsmart segment. The historical results of our Homecare TM Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Revenue: Clinical and Financial Solutions $ 282,254 $ 282,542 $ 553,908 $ 546,417 Population Health 54,026 55,049 108,870 110,282 Netsmart 44,233 0 44,233 0 Unallocated Amounts 6,008 14,127 25,068 29,571 Total revenue $ 386,521 $ 351,718 $ 732,079 $ 686,270 Gross Profit: Clinical and Financial Solutions $ 121,319 $ 112,995 $ 235,519 $ 211,268 Population Health 38,775 36,852 78,732 72,575 Netsmart 14,949 0 14,949 0 Unallocated Amounts (8,359 ) (6,223 ) (10,618 ) (10,429 ) Total gross profit $ 166,684 $ 143,624 $ 318,582 $ 273,414 Income (loss) from operations: Clinical and Financial Solutions $ 67,386 $ 57,518 $ 128,403 $ 100,703 Population Health 24,028 22,734 49,288 43,480 Netsmart (2,399 ) 0 (2,399 ) 0 Unallocated Amounts (70,441 ) (74,661 ) (144,822 ) (144,287 ) Total income (loss) from operations $ 18,574 $ 5,591 $ 30,470 $ (104 )

Basis of Presentation and Sig20

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and six months ended June 30, 2016 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the full year ending December 31, 2016. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2015 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic In March 2016, the FASB issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2016
Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary allocation of the purchase consideration as of the acquisition date: (In thousands) Cash and cash equivalents $ 5,982 Accounts receivable, net 54,510 Prepaid expenses and other current assets 9,266 Fixed assets 26,829 Intangible assets 397,500 Goodwill 625,273 Other assets 6,542 Accounts payable (14,151 ) Accrued expenses (11,690 ) Deferred revenue (18,843 ) Capital lease obligations (17,833 ) Deferred taxes, net (122,646 ) Other liabilities (3,673 ) Net assets acquired $ 937,066
Acquired Intangible Assets Amortization	The acquired intangible assets are being amortized over their useful lives, using a method that approximates the pattern of economic benefits to be gained by the intangible asset and consist of the following amounts for each class of acquired intangible asset: (Dollar amounts in thousands) Useful Life Description in Years Fair Value Technology 10-12 yrs $ 143,000 Corporate Trademark indefinite 27,000 Product Trademarks 10 yrs 8,500 Customer Relationships 12-20 yrs 219,000 $ 397,500
Netsmart Inc [Member]
Sources of Funds Used in Acquisition	The sources of funds used in connection with the Netsmart Acquisition are as follows: (In thousands) Cash contribution for redeemable convertible non-controlling interest in Netsmart - GI Partners $ 333,606 Exchange of Netsmart, Inc.'s common stock for redeemable convertible non-controlling interest in Netsmart - Netsmart, Inc. management 25,543 Cash contribution from borrowings under revolver in exchange for common stock in Netsmart - Allscripts 43,782 Net borrowings under new term loans - Netsmart 534,135 Total funds used for the acquisition $ 937,066
Proforma Results	The revenue and net loss of Netsmart since April 19, 2016 are included in our consolidated statement of operations for the three months ended June 30, 2016 and the supplemental pro forma revenue and net loss of the combined entity, presented as if the acquisition of Netsmart, Inc. had occurred on January 1, 2015, are as follows: Three Months Ended June 30, Six Months Ended June 30, (In thousands, except per share amounts) 2016 2015 2016 2015 Actual from Netsmart since acquisition date of April 19, 2016: Revenue $ 44,233 $ 0 $ 44,233 $ 0 Net loss $ (7,113 ) $ 0 $ (7,113 ) $ 0 Supplemental pro forma data for combined entity: Revenue $ 403,388 $ 391,238 $ 798,395 $ 756,268 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (45,442 ) $ (23,602 ) $ (61,202 ) $ (67,036 ) Loss per share, basic and diluted $ (0.24 ) $ (0.13 ) $ (0.33 ) $ (0.37 )

Fair Value Measurements and I22

Fair Value Measurements and Investments (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet June 30, 2016 December 31, 2015 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total 1.25% Call Option Other assets $ 0 $ 0 $ 38,498 $ 38,498 $ 0 $ 0 $ 80,208 $ 80,208 NantHealth Common Stock Long-term marketable securities 187,500 0 0 187,500 0 0 0 0 1.25% Embedded cash conversion option Other liabilities 0 0 (39,240 ) (39,240 ) 0 0 (81,210 ) (81,210 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 638 0 638 0 424 0 424 Foreign exchange derivative liabilities Accrued expenses 0 0 0 0 0 0 0 0 Total $ 187,500 $ 638 $ (742 ) $ 187,396 $ 0 $ 424 $ (1,002 ) $ (578 )
Summary of Equity Investments Included in Other Assets	The following table summarizes our equity investments which are included in other assets in the accompanying consolidated balance sheet: Number of Original Carrying Value at (In thousands) Investees Investment June 30, 2016 December 31, 2015 Equity method investments (1): Nant Health, LLC (2) 0 0 0 203,117 Other 3 1,658 2,436 2,436 Total equity method investments 3 1,658 2,436 205,553 Cost method investments 5 29,991 26,041 17,876 Total equity investments 8 $ 31,649 $ 28,477 $ 223,429 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. (2) As noted below, effective June 2, 2016, Nant Health LLC is no longer accounted for under the equity method.
Summarized Financial Information for Equity Method Investments	Summarized financial information for our equity method investments on an aggregated basis since the date of acquisition is as follows: March 31, December 31, (In thousands) 2016 2015 Current assets $ 69,491 $ 42,239 Noncurrent assets 571,076 397,519 Current liabilities 214,690 52,482 Noncurrent liabilities 45,920 191,563 Equity of equity method investments $ 379,957 $ 195,713 (In thousands) Trailing Three Months Ended March 31, 2016 Trailing Three Months Ended March 31, 2015 Trailing Six Months Ended March 31, 2016 Trailing Six Months Ended March 31, 2015 Revenue $ 28,557 $ 3,019 $ 51,893 $ 5,729 Net loss (35,385 ) 234 (59,925 ) 18 Long-Term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility and Netsmart’s Credit Agreements (as defined in Note 8, Debt), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as of June 30, 2016, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 8, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2016
Capital Unit [Line Items]
Stock-Based Compensation Expense	Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Cost of revenue: Software delivery, support and maintenance $ 1,061 $ 1,179 $ 2,230 $ 2,275 Client services 1,138 1,322 2,628 2,730 Total cost of revenue 2,199 2,501 4,858 5,005 Selling, general and administrative expenses 6,342 5,200 11,508 10,211 Research and development 2,119 2,317 4,695 4,320 Total stock-based compensation expense $ 10,660 $ 10,018 $ 21,061 $ 19,536
Stock-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Weighted-Average Weighted-Average Grant Date Grant Date (In thousands, except per share amounts) Shares Fair Value Shares Fair Value Service-based restricted stock units 193 $ 13.26 1,995 $ 13.14 Performance-based restricted stock units with a service condition 0 $ 0.00 545 $ 12.39 Market-based restricted stock units with a service condition 0 $ 0.00 621 $ 13.49 193 $ 13.26 3,161 $ 13.08
Netsmart Inc [Member]
Capital Unit [Line Items]
Stock-Based Compensation Expense	The compensation expense was included in the following categories in Netsmart’s statements of operations: (in thousands) June 30, 2016 Cost of sales $ 62 Research and development 36 Sales and marketing 93 General and administrative 1,235 Total $ 1,426
Netsmart Inc [Member] | Class B Non Voting Common Units
Capital Unit [Line Items]
Schedule of Option Units Outstanding	Option Units outstanding at June 30, 2016 are as follows: (Units in thousands) Outstanding Exercisable Exercise price Units Average Black-Scholes Value Weighted Average Remaining Life Shares Average Black-Scholes Value Weighted Average Remaining Life $ 1.00 87,989 $ 0.46 7.00 0 $ 0.00 0
Schedule of Fair Value of Option Units Weighted Average Assumptions	The fair value of Option Units granted during the period from April 19, 2016 through June 30, 2016 was estimated using the Black‑Scholes‑Merton option pricing model using the following weighted average assumptions: Average expected term in years 7.0 Risk free rate (weighted average) 1.3 % Expected dividends 0.0 % Average volatility 43.4 %
Netsmart Inc [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member]
Capital Unit [Line Items]
Summary of the Activity Under the Plan	A summary of the activity under the Plan is as follows: (Units in thousands) Option Units Weighted Average Exercise Price Granted during the period 87,989 $ 1.00 Options called during the period 0 $ 0.00 Options exercised during the period 0 $ 0.00 Forfeited during the period 0 $ 0.00 Outstanding – June 30, 2016 87,989 $ 1.00 Exercisable – June 30, 2016 0 $ 0.00

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended June 30, Six Months Ended June 30, (In thousands, except per share amounts) 2016 2015 2016 2015 Basic Loss per Common Share: Net loss $ (2,136 ) $ (3,216 ) $ (9 ) $ (13,300 ) Less: Net loss (income) attributable to non-controlling interest $ 87 $ (9 ) $ 9 $ (9 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest $ (8,153 ) $ 0 $ (8,153 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (10,202 ) $ (3,225 ) $ (8,153 ) $ (13,309 ) Weighted-average common shares outstanding 186,792 181,558 187,676 181,072 Basic Loss per Common Share $ (0.05 ) $ (0.01 ) $ (0.04 ) $ (0.07 ) Diluted Loss per Common Share: Net loss $ (2,136 ) $ (3,216 ) $ (9 ) $ (13,300 ) Less: Net loss (income) attributable to non-controlling interest $ 87 $ (9 ) $ 9 $ (9 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest $ (8,153 ) $ 0 $ (8,153 ) $ 0 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (10,202 ) $ (3,225 ) $ (8,153 ) $ (13,309 ) Weighted-average common shares outstanding 186,792 181,558 187,676 181,072 Dilutive effect of stock options, restricted stock unit awards and warrants 0 0 0 0 Weighted-average common shares outstanding assuming dilution 186,792 181,558 187,676 181,072 Diluted Loss per Common Share $ (0.05 ) $ (0.01 ) $ (0.04 ) $ (0.07 )
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 25,210 23,759 25,227 23,351

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: June 30, 2016 December 31, 2015 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 593,383 $ (321,221 ) $ 272,162 $ 450,852 $ (302,284 ) $ 148,568 Customer contracts and relationships 779,326 (414,787 ) 364,539 552,395 (405,317 ) 147,078 Total $ 1,372,709 $ (736,008 ) $ 636,701 $ 1,003,247 $ (707,601 ) $ 295,646 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 52,000 Goodwill 1,846,944 1,222,601 Total $ 1,925,944 $ 1,274,601
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the six months ended June 30, 2016 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2015 $ 796,367 $ 426,234 $ 0 $ 1,222,601 Acquisition 0 0 625,273 625,273 Reallocation 0 (37,600 ) 37,600 0 Foreign exchange translation (930 ) 0 0 (930 ) Balance as of June 30, 2016 $ 795,437 $ 388,634 $ 662,873 $ 1,846,944

Asset Impairment Charges (Table

Asset Impairment Charges (Tables)	6 Months Ended
	Jun. 30, 2016
Asset Impairment Charges [Abstract]
Asset Impairment Charges	We incurred the following impairment charges: Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 (In thousands) 2016 2015 2016 2015 Asset impairment charges $ 0 $ 293 $ 4,650 $ 319

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Instrument [Line Items]
Debt Outstanding Excluding Capital Leases	Debt outstanding, excluding capital leases, consisted of the following: June 30, 2016 December 31, 2015 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 55,554 $ 289,446 $ 345,000 $ 61,771 $ 283,229 Senior Secured Credit Facility 360,625 5,366 355,259 346,875 5,704 341,171 Netsmart Non-Recourse Debt: First Lien Term Loan 395,000 17,319 377,681 0 0 0 Second Lien Term Loan 167,000 9,698 157,302 0 0 0 Other debt 71 0 71 183 0 183 Total debt $ 1,267,696 $ 87,937 $ 1,179,759 $ 692,058 $ 67,475 $ 624,583 Less debt payable within one year 12,570 493 12,077 12,657 479 12,178 Less debt payable within one year - Netsmart 15,800 4,198 11,602 0 0 0 Total long-term debt, less current maturities $ 1,239,326 $ 83,246 $ 1,156,080 $ 679,401 $ 66,996 $ 612,405
Summary of Future Payment Obligations under Debt	The following table summarizes our future payment obligations under our debt as of June 30, 2016: (In thousands) Total Remainder of 2016 2017 2018 2019 2020 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 0 $ 345,000 $ 0 Term Loan 240,625 6,250 15,625 28,125 40,625 150,000 0 Revolving Facility 120,000 0 0 0 0 120,000 0 Netsmart Non-Recourse Debt: First Lien Term Loan 395,000 7,900 15,800 15,800 15,800 15,800 323,900 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Other debt 71 71 0 0 0 0 0 Total debt $ 1,267,696 $ 14,221 $ 31,425 $ 43,925 $ 56,425 $ 630,800 $ 490,900 (1)
Interest Expense	Interest expense consisted of the following: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Interest expense $ 3,595 $ 4,008 $ 7,133 $ 7,869 Amortization of discounts and debt issuance costs 3,448 3,418 6,879 6,813 Write off of unamortized deferred debt issuance costs 0 57 0 57 Netsmart: Interest expense (1) 8,530 0 8,530 0 Amortization of discounts and debt issuance costs 848 0 848 0 Total interest expense $ 16,421 $ 7,483 $ 23,390 $ 14,739 (1) Includes interest expense related to capital leases.
1.25% Cash Convertible Senior Notes [Member]
Interest Expense	Interest expense related to the 1.25% Notes was comprised of the following: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Coupon interest at 1.25% $ 1,078 $ 1,078 $ 2,156 $ 2,156 Amortization of discounts and debt issuance costs 3,108 2,977 6,216 5,925 Total interest expense related to the 1.25% Notes $ 4,186 $ 4,055 $ 8,372 $ 8,081

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Effective Tax Rates	Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Income (loss) before income taxes $ (2,639 ) $ (1,744 ) $ 51 $ (12,809 ) Income tax benefit (provision) $ 503 $ (1,472 ) $ (60 ) $ (491 ) Effective tax rate 19.1 % (84.4 %) 117.6 % (3.8 %)

Derivative Financial Instrume29

Derivative Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: June 30, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 638 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 38,498 N/A 1.25% Embedded cash conversion option N/A Other liabilities 39,240 Total derivatives $ 39,136 $ 39,240 December 31, 2015 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 424 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 80,208 N/A 1.25% Embedded cash conversion option N/A Other liabilities 81,210 Total derivatives $ 80,632 $ 81,210 N/A – We define “N/A” as disclosure not being applicable
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended June 30, 2016 Six Months Ended June 30, 2016 Foreign exchange contracts $ (141 ) $ 201 Cost of Revenue $ 27 $ (4 ) Selling, general and administrative expenses 22 (3 ) Research and development 37 (6 ) Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended June 30, 2015 Six Months Ended June 30, 2015 Foreign exchange contracts $ 230 $ 230 Cost of Revenue $ 0 $ 0 Selling, general and administrative expenses 0 0 Research and development 0 0
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option	The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes embedded cash conversion option in the consolidated statements of operations: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 1.25% Call Option $ (10,507 ) $ 17,064 $ (41,710 ) $ 9,855 1.25% Embedded cash conversion option 10,577 (17,248 ) 41,970 (10,014 ) Net gain (loss) included in other income, net $ 70 $ (184 ) $ 260 $ (159 )

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Marketable Securities (3) Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive (loss) income before reclassifications (199 ) (18,115 ) 121 (18,193 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 8 8 Net other comprehensive (loss) income (199 ) (18,115 ) 129 (18,185 ) Balance as of June 30, 2016 (2) $ (4,699 ) $ (18,115 ) $ 387 $ (22,427 ) (1) (2) (3) Marketable securities represent NantHealth common stock (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Marketable Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2014 (1) $ (2,119 ) $ 140 $ 0 $ (1,979 ) Other comprehensive (loss) income before reclassifications (391 ) 0 140 (251 ) Net gains reclassified from accumulated other comprehensive loss 0 (140 ) 0 (140 ) Net other comprehensive (loss) income (391 ) (140 ) 140 (391 ) Balance as of June 30, 2015 (2) $ (2,510 ) $ 0 $ 140 $ (2,370 ) (1) (2)
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended June 30, 2016 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (943 ) $ 0 $ (943 ) $ 677 $ 0 $ 677 Marketable securities: Net loss arising during the period (18,115 ) 0 (18,115 ) 0 0 0 Net gain reclassified into income 0 0 0 0 0 0 Net change in unrealized losses on marketable securities (18,115 ) 0 (18,115 ) 0 0 0 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period (141 ) 55 (86 ) 230 (90 ) 140 Net (gains) losses reclassified into income (86 ) 34 (52 ) 0 0 0 Net change in unrealized (losses) gains on foreign exchange contracts (227 ) 89 (138 ) 230 (90 ) 140 Net (loss) gain on cash flow hedges (227 ) 89 (138 ) 230 (90 ) 140 Other comprehensive (loss) income $ (19,285 ) $ 89 $ (19,196 ) $ 907 $ (90 ) $ 817 Six Months Ended June 30, 2016 2015 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ (199 ) $ 0 $ (199 ) $ (391 ) $ 0 $ (391 ) Marketable securities: Net loss arising during the period (18,115 ) 0 (18,115 ) 0 0 0 Net (gain) loss reclassified into income 0 0 0 (228 ) 88 (140 ) Net change in unrealized (losses) gains on marketable securities (18,115 ) 0 (18,115 ) (228 ) 88 (140 ) Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net gains (losses) arising during the period 201 (80 ) 121 230 (90 ) 140 Net (gains) losses reclassified into income 13 (5 ) 8 0 0 0 Net change in unrealized gains (losses) on foreign exchange contracts 214 (85 ) 129 230 (90 ) 140 Net gain (loss) on cash flow hedges 214 (85 ) 129 230 (90 ) 140 Other comprehensive loss $ (18,100 ) $ (85 ) $ (18,185 ) $ (389 ) $ (2 ) $ (391 )

Business Segments (Tables)

Business Segments (Tables)	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2016 2015 2016 2015 Revenue: Clinical and Financial Solutions $ 282,254 $ 282,542 $ 553,908 $ 546,417 Population Health 54,026 55,049 108,870 110,282 Netsmart 44,233 0 44,233 0 Unallocated Amounts 6,008 14,127 25,068 29,571 Total revenue $ 386,521 $ 351,718 $ 732,079 $ 686,270 Gross Profit: Clinical and Financial Solutions $ 121,319 $ 112,995 $ 235,519 $ 211,268 Population Health 38,775 36,852 78,732 72,575 Netsmart 14,949 0 14,949 0 Unallocated Amounts (8,359 ) (6,223 ) (10,618 ) (10,429 ) Total gross profit $ 166,684 $ 143,624 $ 318,582 $ 273,414 Income (loss) from operations: Clinical and Financial Solutions $ 67,386 $ 57,518 $ 128,403 $ 100,703 Population Health 24,028 22,734 49,288 43,480 Netsmart (2,399 ) 0 (2,399 ) 0 Unallocated Amounts (70,441 ) (74,661 ) (144,822 ) (144,287 ) Total income (loss) from operations $ 18,574 $ 5,591 $ 30,470 $ (104 )

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 19, 2016	Jun. 30, 2016	Jun. 30, 2016
Business Acquisition [Line Items]
Contribution and investment agreement date			Mar. 20, 2016
Netsmart transaction completion date			Apr. 19, 2016
Description of liquidation preference			The liquidation preference is equal to the greater of (i) a return of the original issue price plus a preferred return (accruing on a daily basis at the rate of 11% per annum and compounding annually on the last day of each calendar year) or (ii) the as-converted value of Class A Common Units in Nathan.
Preferred return percentage			11.00%
Percentage of redemption preference		11.00%	11.00%
Equity ownership percentage	49.10%
Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition-related costs		$ 400	$ 4,100
GI Partners [Member]
Business Acquisition [Line Items]
Equity ownership percentage	47.20%
Netsmart Management [Member]
Business Acquisition [Line Items]
Minority interest percentage	3.70%
Netsmart Inc [Member]
Business Acquisition [Line Items]
Business combination, purchase price	$ 950,000
Escrow deposit related to the integration of homecare business	$ 15,000
Escrow deposit period	5 years
Business combination, aggregate consideration	$ 937,066
Extinguishment of debt	325,000
Accrued interest and fees	2,000
Netsmart Inc [Member] | Outstanding Equity Awards and Seller Costs [Member]
Business Acquisition [Line Items]
Expenses incurred in acquisition		$ 48,600	$ 48,600
Netsmart Inc [Member] | Nathan [Member]
Business Acquisition [Line Items]
Business combination, aggregate consideration	$ 937,000

Schedule of Purchase Price Fund

Schedule of Purchase Price Funded by the Sources of Funds (Detail) - Netsmart Inc [Member] $ in Thousands	Apr. 19, 2016USD ($)
Business Acquisition [Line Items]
Net borrowings under new term loans	$ 534,135
Business combination, aggregate consideration	937,066
GI Partners [Member]
Business Acquisition [Line Items]
Cash contribution for redeemable convertible non-controlling interest	333,606
Netsmart Inc Management [Member]
Business Acquisition [Line Items]
Exchange of Netsmart common stock for redeemable convertible non-controlling interest	25,543
Allscripts [Member]
Business Acquisition [Line Items]
Cash contribution from borrowings under revolver in exchange for common stock	$ 43,782

Assets Acquired and Liabilities

Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Apr. 19, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 1,846,944		$ 1,222,601
Netsmart Inc [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		$ 5,982
Accounts receivable, net		54,510
Prepaid expenses and other current assets		9,266
Fixed assets		26,829
Intangible assets		397,500
Goodwill		625,273
Other assets		6,542
Accounts payable		(14,151)
Accrued expenses		(11,690)
Deferred revenue		(18,843)
Capital lease obligations		(17,833)
Deferred taxes, net		(122,646)
Other liabilities		(3,673)
Net assets acquired		$ 937,066

Acquired Intangible Assets Amor

Acquired Intangible Assets Amortization (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Business Acquisition [Line Items]
Intangible assets, fair value	$ 397,500
Technology [member]
Business Acquisition [Line Items]
Intangible assets, fair value	143,000
Corporate Trademark [member]
Business Acquisition [Line Items]
Intangible assets, fair value	$ 27,000
Product Trademarks [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	10 years
Intangible assets, fair value	$ 8,500
Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets, fair value	$ 219,000
Minimum [Member] | Technology [member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	10 years
Minimum [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	12 years
Maximum [Member] | Technology [member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	12 years
Maximum [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets, useful life (in years)	20 years

Pro forma Results (Detail)

Pro forma Results (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Netsmart Inc [Member]
Business Acquisition [Line Items]
Revenue	$ 44,233	$ 0	$ 44,233	$ 0
Net loss	(7,113)	0	(7,113)	0
Combined Entity [Member]
Business Acquisition [Line Items]
Revenue	403,388	391,238	798,395	756,268
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (45,442)	$ (23,602)	$ (61,202)	$ (67,036)
Loss per share, basic and diluted	$ (0.24)	$ (0.13)	$ (0.33)	$ (0.37)

Summary of Financial Assets and

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term marketable securities	$ 187,500	$ 0
Prepaid expenses and other current assets	107,810	93,622
Accrued expenses	(65,696)	(62,021)
Total	187,396	(578)
NantHealth Common Stock [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term marketable securities	187,500	0
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	638	424
Foreign exchange derivative liabilities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(39,240)	(81,210)
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	38,498	80,208
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	187,500	0
Level 1 [Member] | NantHealth Common Stock [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term marketable securities	187,500	0
Level 1 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] | Foreign exchange derivative liabilities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	638	424
Level 2 [Member] | NantHealth Common Stock [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term marketable securities	0	0
Level 2 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	638	424
Level 2 [Member] | Foreign exchange derivative liabilities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	(742)	(1,002)
Level 3 [Member] | NantHealth Common Stock [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Long-term marketable securities	0	0
Level 3 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] | Foreign exchange derivative liabilities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(39,240)	(81,210)
Level 3 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 38,498	$ 80,208

Summary of Equity Investments I

Summary of Equity Investments Included in Other Assets (Detail) $ in Thousands		6 Months Ended
		Jun. 30, 2016USD ($)Investment	Dec. 31, 2015USD ($)
Schedule Of Investments [Line Items]
Number of Investees | Investment	[1]	3
Equity method investments, Original Investment	[1]	$ 1,658
Equity method investments, Carrying Value	[1]	$ 2,436	$ 205,553
Cost method investments, Number of Investees | Investment		5
Cost method investments, Original Investment		$ 29,991
Cost method investments, Carrying Value		$ 26,041	17,876
Total equity investments, Number of Investees | Investment		8
Total equity investments, Original Investment		$ 31,649
Total equity investments, Carrying Value		$ 28,477	223,429
Nant Health, LLC [Member]
Schedule Of Investments [Line Items]
Number of Investees | Investment	[1],[2]	0
Equity method investments, Original Investment	[1],[2]	$ 0
Equity method investments, Carrying Value	[1],[2]	$ 0	203,117
Other [Member]
Schedule Of Investments [Line Items]
Number of Investees | Investment	[1]	3
Equity method investments, Original Investment	[1]	$ 1,658
Equity method investments, Carrying Value	[1]	$ 2,436	$ 2,436
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.
[2]	As noted below, effective June 2, 2016, Nant Health LLC is no longer accounted for under the equity method.

Fair Value Measurements and I39

Fair Value Measurements and Investments - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		Jun. 02, 2016	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 01, 2016	Dec. 31, 2015
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Common stock, shares issued			267,844,000			267,844,000			266,545,000
Carrying values of equity method investment	[1]		$ 2,436			$ 2,436			$ 205,553
Closing price of fair value investment			187,500			187,500			0
Unrealized loss of fair value investment			(19,196)		$ 817	(18,185)	$ (391)
Asset impairment charges			0		$ 293	4,650	$ 319
Total consideration for non marketable equity securities				$ 500
Total consideration for non marketable equity securities						10,200
Carrying values of cost method investments			$ 26,041			$ 26,041			$ 17,876
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate			1.25%			1.25%
Other Assets [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Convertible note fair value			$ 500			$ 500
Carrying values of cost method investments			$ 10,200			10,200
Cost Method Equity Investments
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Asset impairment charges						$ 2,100
NantHealth, Inc [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Minority ownership percentage by parent			12.40%			12.40%
Aggregate voting interest on common stock		15,000,000
Common Stock shares voting percent		12.40%
Carrying values of equity method investment			$ 205,600			$ 205,600
NantHealth, Inc [Member] | IPO [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Common stock, shares issued		6,500,000						14,285,714
Minority ownership percentage by parent		11.80%						12.60%
Additional shares purchased		714,286
Additional shares purchased per share		$ 14
Additional shares purchased investment amount		$ 10,000
NantHealth Common Stock [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Closing price of fair value investment			$ 187,500			187,500
Unrealized loss of fair value investment						$ 18,100
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Summarized Financial Informatio

Summarized Financial Information for Equity Method Investments (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Equity Method Investments And Joint Ventures [Abstract]
Current assets	$ 69,491		$ 69,491		$ 42,239
Noncurrent assets	571,076		571,076		397,519
Current liabilities	214,690		214,690		52,482
Noncurrent liabilities	45,920		45,920		191,563
Equity of equity method investments	379,957		379,957		$ 195,713
Revenue	28,557	$ 3,019	51,893	$ 5,729
Net loss	$ (35,385)	$ 234	$ (59,925)	$ 18

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	2 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2015USD ($)shares	Jun. 30, 2016USD ($)Installment$ / sharesshares	Jun. 30, 2015USD ($)shares	Dec. 31, 2015$ / sharesshares	Nov. 30, 2015USD ($)
Class Of Stock [Line Items]
Capitalized stock-based compensation costs | $		$ 0	$ 0	$ 0	$ 0
Stock options granted | shares		0	0	0	0
Share issued, exercise of options and release of stock awards | shares				1,300,000		1,400,000
Shares settled for tax withholding | shares				564,000	422,000
Stock repurchase program, authorized amount | $							$ 150,000,000
Common stock repurchased, shares | shares		1,200,000		4,100,000
Common stock repurchased, amount | $		$ 14,500,000		$ 52,075,000	$ 0
Remaining value for purchase of common stock under the stock repurchase program | $	$ 98,000,000	$ 98,000,000		$ 98,000,000
Unregistered common stock, shares issued | shares	267,844,000	267,844,000		267,844,000		266,545,000
Common stock, par value | $ / shares	$ 0.01	$ 0.01		$ 0.01		$ 0.01
Stock based compensation expense | $		$ 10,660,000	$ 10,018,000	$ 21,061,000	$ 19,536,000
Netsmart Inc [Member]
Class Of Stock [Line Items]
Stock based compensation expense | $				1,426,000
Liability for outstanding awards | $	$ 1,400,000	$ 1,400,000		$ 1,400,000
Estimated weighted average fair value, Black-Scholes-Merton option pricing model | $ / shares	$ 0.46	$ 0.46		$ 0.46
Estimated share price | $ / shares	$ 1	$ 1		$ 1
Share based compensation expense remaining to be recognized | $	$ 27,500,000	$ 27,500,000		$ 27,500,000
Share based compensation expense remaining to be recognized, 2016 | $	3,600,000	3,600,000		3,600,000
Share based compensation expense remaining to be recognized, 2017 | $	7,200,000	7,200,000		7,200,000
Share based compensation expense remaining to be recognized, 2018 | $	7,200,000	7,200,000		7,200,000
Share based compensation expense remaining to be recognized, 2019 | $	7,200,000	7,200,000		7,200,000
Share based compensation expense remaining to be recognized, 2020 | $	$ 2,300,000	2,300,000		2,300,000
Netsmart Inc [Member] | Class B Non Voting Common Units
Class Of Stock [Line Items]
Options issued during the period | shares	87,989,000
Exercise price | $ / shares	$ 1
Intrinsic value related to outstanding Option Units | $	$ 0	$ 0		$ 0
Estimated weighted average fair value, Black-Scholes-Merton option pricing model | $ / shares	$ 0.46	$ 0.46		$ 0.46
Netsmart Inc [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member]
Class Of Stock [Line Items]
Stock options granted | shares	87,989,000
Maximum issuance of options | shares	116,491,000	116,491,000		116,491,000
Options available for further issuance | shares	28,502,000	28,502,000		28,502,000
Exercise price | $ / shares	$ 1
Netsmart Inc [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member] | Time Based Option Units [Member]
Class Of Stock [Line Items]
Options issued during the period | shares	62,849,000
Exercise price | $ / shares	$ 1
Options vesting period	4 years
Vesting description				The Option Units vest ratably over a period of four years, with the first twenty-five percent vesting at the first anniversary of the issuance and the remaining vesting in equal monthly increments over the following thirty-six months
Netsmart Inc [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member] | Performance Based Option Units [Member]
Class Of Stock [Line Items]
Options issued during the period | shares	25,140,000
Exercise price | $ / shares	$ 1
Stock based compensation expense | $				$ 0
Netsmart Inc [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member] | Maximum [Member]
Class Of Stock [Line Items]
Option Units expiration period				10 years
Customary Anti-Dilution Adjustments [Member] | Warrant Issued to Commercial Partner [Member]
Class Of Stock [Line Items]
Number of installments | Installment				4
Number of warrants vesting annually | shares	750,000	750,000		750,000
Warrant expiration period				2026-06
Case 1 [Member] | Customary Anti-Dilution Adjustments [Member] | Warrant Issued to Commercial Partner [Member]
Class Of Stock [Line Items]
Number of warrants issued | shares	900,000	900,000		900,000
Common stock, par value | $ / shares	$ 0.01	$ 0.01		$ 0.01
Sale of common stock, price per share | $ / shares	$ 12.47	$ 12.47		$ 12.47
Case 2 [Member] | Customary Anti-Dilution Adjustments [Member] | Warrant Issued to Commercial Partner [Member]
Class Of Stock [Line Items]
Number of warrants issued | shares	1,000,000	1,000,000		1,000,000
Sale of common stock, price per share | $ / shares	$ 14.34	$ 14.34		$ 14.34
Case 3 [Member] | Customary Anti-Dilution Adjustments [Member] | Warrant Issued to Commercial Partner [Member]
Class Of Stock [Line Items]
Number of warrants issued | shares	1,100,000	1,100,000		1,100,000
Sale of common stock, price per share | $ / shares	$ 15.59	$ 15.59		$ 15.59

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 10,660	$ 10,018	$ 21,061	$ 19,536
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	2,199	2,501	4,858	5,005
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,061	1,179	2,230	2,275
Cost of revenue [Member] | Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,138	1,322	2,628	2,730
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	6,342	5,200	11,508	10,211
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 2,119	$ 2,317	$ 4,695	$ 4,320

Stock-Based Awards Granted (Det

Stock-Based Awards Granted (Detail) - $ / shares shares in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	193	3,161
Weighted-Average Grant Date Fair Value, granted	$ 13.26	$ 13.08
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	193	1,995
Weighted-Average Grant Date Fair Value, granted	$ 13.26	$ 13.14
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	545
Weighted-Average Grant Date Fair Value, granted	$ 0	$ 12.39
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	621
Weighted-Average Grant Date Fair Value, granted	$ 0	$ 13.49

Summary of the Activity Under t

Summary of the Activity Under the Plan (Detail) - $ / shares	2 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option Units, Granted during the period		0	0	0	0
Netsmart Inc [Member] | Nathan Holding LLC 2016 Unit Option Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option Units, Granted during the period	87,989,000
Option Units, Options called during the period	0
Option Units, Options exercised during the period	0
Option Units, Forfeited during the period	0
Option Units, Outstanding – June 30, 2016	87,989,000	87,989,000		87,989,000
Option Units, Exercisable – June 30, 2016	0	0		0
Weighted Average Exercise Price, Granted during the period	$ 1
Weighted Average Exercise Price, Options called during the period	0
Weighted Average Exercise Price, Options exercised during the period	0
Weighted Average Exercise Price, Forfeited during the period	0
Weighted Average Exercise Price, Outstanding – June 30, 2016	1	$ 1		$ 1
Weighted Average Exercise Price, Exercisable – June 30, 2016	$ 0	$ 0		$ 0

Schedule of Option Units Outsta

Schedule of Option Units Outstanding (Detail) - Netsmart Inc [Member]	2 Months Ended
	Jun. 30, 2016$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding, Average Black-Scholes Value	$ 0.46
Class B Non Voting Common Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 1
Option Units, Outstanding – June 30, 2016 | shares	87,989,000
Outstanding, Average Black-Scholes Value	$ 0.46
Outstanding, Weighted Average Remaining Life	7 years
Option Units, Exercisable – June 30, 2016 | shares	0
Exercisable, Average Black-Scholes Value	$ 0
Exercisable, Weighted Average Remaining Life	0 years

Schedule of Compensation Expens

Schedule of Compensation Expense Categories in Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total compensation expense	$ 10,660	$ 10,018	$ 21,061	$ 19,536
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total compensation expense	2,199	2,501	4,858	5,005
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total compensation expense	$ 2,119	$ 2,317	4,695	$ 4,320
Netsmart Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total compensation expense			1,426
Netsmart Inc [Member] | Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total compensation expense			62
Netsmart Inc [Member] | Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total compensation expense			36
Netsmart Inc [Member] | Selling and Marketing Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total compensation expense			93
Netsmart Inc [Member] | General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total compensation expense			$ 1,235

Schedule of Fair Value of Optio

Schedule of Fair Value of Option Units Weighted Average Assumptions (Detail) - Netsmart Inc [Member] - Class B Non Voting Common Units	2 Months Ended
	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Average expected term in years	7 years
Risk free rate (weighted average)	1.30%
Expected dividends	0.00%
Average volatility	43.40%

Calculations of Earnings (Loss)

Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Basic Loss per Common Share:
Net loss	$ (2,136)	$ (3,216)	$ (9)	$ (13,300)
Less: Net loss (income) attributable to non-controlling interest	87	(9)	9	(9)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest	(8,153)	0	(8,153)	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (10,202)	$ (3,225)	$ (8,153)	$ (13,309)
Weighted-average common shares outstanding	186,792	181,558	187,676	181,072
Basic Loss per Common Share	$ (0.05)	$ (0.01)	$ (0.04)	$ (0.07)
Diluted Loss per Common Share:
Net loss	$ (2,136)	$ (3,216)	$ (9)	$ (13,300)
Less: Net loss (income) attributable to non-controlling interest	87	(9)	9	(9)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest	(8,153)	0	(8,153)	0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (10,202)	$ (3,225)	$ (8,153)	$ (13,309)
Weighted-average common shares outstanding	186,792	181,558	187,676	181,072
Dilutive effect of stock options, restricted stock unit awards and warrants	0	0	0	0
Weighted-average common shares outstanding assuming dilution	186,792	181,558	187,676	181,072
Diluted Loss per Common Share	$ (0.05)	$ (0.01)	$ (0.04)	$ (0.07)

Anti-Dilutive Stock Options, Re

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	25,210	23,759	25,227	23,351

Goodwill and Intangible Asset50

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,372,709	$ 1,003,247
Accumulated Amortization	(736,008)	(707,601)
Intangible Assets, Net	636,701	295,646
Registered trademarks	79,000	52,000
Goodwill	1,846,944	1,222,601
Total	1,925,944	1,274,601
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	593,383	450,852
Accumulated Amortization	(321,221)	(302,284)
Intangible Assets, Net	272,162	148,568
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	779,326	552,395
Accumulated Amortization	(414,787)	(405,317)
Intangible Assets, Net	$ 364,539	$ 147,078

Changes in Carrying Amount of G

Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Goodwill [Line Items]
Goodwill	$ 1,222,601
Acquisition	625,273
Reallocation	0
Foreign exchange translation	(930)
Goodwill, net	1,846,944
Clinical and Financial Solutions [Member]
Goodwill [Line Items]
Goodwill	796,367
Acquisition	0
Reallocation	0
Foreign exchange translation	(930)
Goodwill, net	795,437
Population Health [Member]
Goodwill [Line Items]
Goodwill	426,234
Acquisition	0
Reallocation	(37,600)
Foreign exchange translation	0
Goodwill, net	388,634
Netsmart [Member]
Goodwill [Line Items]
Goodwill	0
Acquisition	625,273
Reallocation	37,600
Foreign exchange translation	0
Goodwill, net	$ 662,873

Goodwill and Intangible Asset52

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Accumulated impairment losses associated with goodwill	$ 0	$ 0

Asset Impairment Charges (Detai

Asset Impairment Charges (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Asset Impairment Charges [Abstract]
Asset impairment charges	$ 0	$ 293	$ 4,650	$ 319

Asset Impairment Charges - Addi

Asset Impairment Charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Asset Impairment Charges [Line Items]
Asset impairment charges	$ 0	$ 293	$ 4,650	$ 319
Other charges			400
Capitalized Software Development Projects [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges			2,200
Cost Method Equity Investments
Asset Impairment Charges [Line Items]
Asset impairment charges			$ 2,100

Debt Outstanding Excluding Capi

Debt Outstanding Excluding Capital Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2016		Dec. 31, 2015
Debt Instrument [Line Items]
Principal Balance	$ 1,267,696		$ 692,058
Unamortized Discount and Debt Issuance Costs	87,937		67,475
Net Carrying Amount	1,179,759		624,583
Principal Balance, Current	12,570		12,657
Unamortized Discount and Debt Issuance Costs, Current	493		479
Net Carrying Amount, Current	12,077		12,178
Principal Balance, Noncurrent	1,239,326		679,401
Unamortized Discount and Debt Issuance Costs, Noncurrent	83,246		66,996
Net Carrying Amount, Noncurrent	1,156,080		612,405
Netsmart [Member]
Debt Instrument [Line Items]
Principal Balance, Current	15,800		0
Unamortized Discount and Debt Issuance Costs, Current	4,198		0
Net Carrying Amount, Current	11,602		0
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	345,000	[1]	345,000
Unamortized Discount and Debt Issuance Costs	55,554		61,771
Net Carrying Amount	289,446		283,229
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	360,625		346,875
Unamortized Discount and Debt Issuance Costs	5,366		5,704
Net Carrying Amount	355,259		341,171
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	395,000		0
Unamortized Discount and Debt Issuance Costs	17,319		0
Net Carrying Amount	377,681		0
Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	167,000		0
Unamortized Discount and Debt Issuance Costs	9,698		0
Net Carrying Amount	157,302		0
Other Debt [Member]
Debt Instrument [Line Items]
Principal Balance	71		183
Unamortized Discount and Debt Issuance Costs	0		0
Net Carrying Amount	$ 71		$ 183
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Interest Expense (Detail)

Interest Expense (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Interest expense		$ 3,595	$ 4,008	$ 7,133	$ 7,869
Amortization of discounts and debt issuance costs		3,448	3,418	6,879	6,813
Write off of unamortized deferred debt issuance costs		0	57	0	57
Total interest expense		16,421	7,483	23,390	14,739
Netsmart [Member]
Debt Instrument [Line Items]
Amortization of discounts and debt issuance costs		848	0	848	0
Interest expense	[1]	$ 8,530	$ 0	$ 8,530	$ 0
[1]	Includes interest expense related to capital leases.

Interest Expense Related to Not

Interest Expense Related to Notes (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Coupon interest at 1.25%	$ 3,595	$ 4,008	$ 7,133	$ 7,869
Amortization of discounts and debt issuance costs	3,448	3,418	6,879	6,813
Total interest expense	16,421	7,483	23,390	14,739
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Coupon interest at 1.25%	1,078	1,078	2,156	2,156
Amortization of discounts and debt issuance costs	3,108	2,977	6,216	5,925
Total interest expense	$ 4,186	$ 4,055	$ 8,372	$ 8,081

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Apr. 19, 2016	Jun. 30, 2016		Mar. 31, 2019	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Debt instrument principal amount		$ 1,267,696,000				$ 692,058,000
Allscripts Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		240,600,000
Allscripts Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		120,000,000
Letters of credit outstanding		800,000
Credit facility, amount available		$ 429,200,000
Allscripts Senior Secured Revolving Facility [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		2.21%
Allscripts Senior Secured Revolving Facility [Member] | LIBO Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread		1.75%
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 345,000,000	[1]			$ 345,000,000
Interest rate		1.25%
Netsmart First Lien Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		5.75%
Netsmart First Lien Credit Agreement [Member] | Scenario Forecast [Member] | Maximum [Member]
Debt Instrument [Line Items]
Leverage ratio					875.00%
Netsmart First Lien Credit Agreement [Member] | Scenario Forecast [Member] | Minimum [Member]
Debt Instrument [Line Items]
Leverage ratio				675.00%
Netsmart First Lien Credit Agreement [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Credit facility, amount available		$ 48,500,000
Credit facility, maximum borrowing capacity	$ 50,000,000
Senior secured credit facilities term, years	5 years
Credit facility termination date	Apr. 19, 2021
Netsmart First Lien Credit Agreement [Member] | Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 395,000,000
Credit facility, maximum borrowing capacity	$ 395,000,000
Senior secured credit facilities term, years	7 years
Credit facility termination date	Apr. 19, 2023
Netsmart First Lien Credit Agreement [Member] | LIBO Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread	4.75%	4.75%
Netsmart First Lien Credit Agreement [Member] | LIBO Rate [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread	4.25%
Netsmart First Lien Credit Agreement [Member] | Alternate Base Rate Loans
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage	3.75%
Netsmart First Lien Credit Agreement [Member] | Alternate Base Rate Loans | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage	3.25%
Netsmart Second Lien Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		10.50%
Netsmart Second Lien Credit Agreement [Member] | Scenario Forecast [Member] | Maximum [Member]
Debt Instrument [Line Items]
Leverage ratio					975.00%
Netsmart Second Lien Credit Agreement [Member] | Scenario Forecast [Member] | Minimum [Member]
Debt Instrument [Line Items]
Leverage ratio				775.00%
Netsmart Second Lien Credit Agreement [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 1,500,000
Netsmart Second Lien Credit Agreement [Member] | Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 167,000,000
Credit facility, maximum borrowing capacity	$ 167,000,000
Senior secured credit facilities term, years	7 years 6 months
Credit facility termination date	Oct. 19, 2023
Netsmart Second Lien Credit Agreement [Member] | LIBO Rate [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread		9.50%
Netsmart Second Lien Credit Agreement [Member] | LIBO Rate [Member] | Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Senior secured credit facility interest rate spread	9.50%
Netsmart Second Lien Credit Agreement [Member] | Alternate Base Rate Loans | Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage	8.50%
Netsmart Credit Agreements [Member]
Debt Instrument [Line Items]
Debt issuance costs capitalized		$ 27,900,000
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Summary of Future Payment Oblig

Summary of Future Payment Obligations under Debt (Detail) - USD ($) $ in Thousands		Jun. 30, 2016		Dec. 31, 2015
Debt Instrument [Line Items]
Total		$ 1,267,696		$ 692,058
Remainder of 2016		14,221
2,017		31,425
2,018		43,925
2,019		56,425
2,020		630,800
Thereafter		490,900
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total		345,000	[1]	345,000
Remainder of 2016	[1]	0
2,017	[1]	0
2,018	[1]	0
2,019	[1]	0
2,020	[1]	345,000
Thereafter	[1]	0
Term Loan [Member]
Debt Instrument [Line Items]
Total		240,625
Remainder of 2016		6,250
2,017		15,625
2,018		28,125
2,019		40,625
2,020		150,000
Thereafter		0
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		395,000		0
Remainder of 2016		7,900
2,017		15,800
2,018		15,800
2,019		15,800
2,020		15,800
Thereafter		323,900
Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		167,000		0
Remainder of 2016		0
2,017		0
2,018		0
2,019		0
2,020		0
Thereafter		167,000
Other Debt [Member]
Debt Instrument [Line Items]
Total		71		$ 183
Remainder of 2016		71
2,017		0
2,018		0
2,019		0
2,020		0
Thereafter		0
Revolving Facility [Member]
Debt Instrument [Line Items]
Total		120,000
Remainder of 2016		0
2,017		0
2,018		0
2,019		0
2,020		120,000
Thereafter		$ 0
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Summary of Future Payment Obl60

Summary of Future Payment Obligations under Debt (Parenthetical) (Detail)	6 Months Ended
	Jun. 30, 2016
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Notes maturity period	Jul. 1, 2020

Effective Tax Rates (Detail)

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income (loss) before income taxes	$ (2,639)	$ (1,744)	$ 51	$ (12,809)
Income tax benefit (provision)	$ 503	$ (1,472)	$ (60)	$ (491)
Effective tax rate	19.10%	(84.40%)	117.60%	(3.80%)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Cumulative operating income loss period considered	3 years
Valuation allowance	$ 0
Unrecognized income tax benefits	$ 13,100,000	$ 11,800,000

Fair Value and Balance Sheet Lo

Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 39,136	$ 80,632
Derivative liability, fair value	39,240	81,210
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	638	424
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	0	0
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	38,498	80,208
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 39,240	$ 81,210

Derivative Financial Instrume64

Derivative Financial Instruments - Additional Information (Detail)	3 Months Ended	6 Months Ended
	Jun. 30, 2016USD ($)Derivative	Jun. 30, 2016USD ($)Derivative	Jun. 30, 2016INR (₨)Derivative	Jun. 30, 2015USD ($)
1.25% Call Option [Member]
Derivative [Line Items]
Interest rate	1.25%	1.25%	1.25%
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts | Derivative	24	24	24
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ 0	$ 0
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	0	0
Unrealized derivatives gains (losses) included in other comprehensive (loss) income reclassified into income		$ 500,000
Estimated period of unrealized gains included in AOCI reclassified into income		12 months
Foreign Exchange Forward Contracts [Member] | Minimum [Member]
Derivative [Line Items]
Date of contracts mature		Jul. 31, 2016
Derivative notional amount outstanding	300,000	$ 300,000	₨ 20,000,000
Foreign Exchange Forward Contracts [Member] | Maximum [Member]
Derivative [Line Items]
Date of contracts mature		Dec. 31, 2017
Derivative notional amount outstanding	$ 2,100,000	$ 2,100,000	₨ 140,000,000
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Interest rate	1.25%	1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option				$ 82,800,000

Derivatives Instruments Designa

Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ (141)	$ 230	$ 201	$ 230
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	27	0	(4)	0
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	22	0	(3)	0
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ 37	$ 0	$ (6)	$ 0

Net Impact of Changes in Fair V

Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	$ 70	$ (184)	$ 260	$ (159)
1.25% Call Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	(10,507)	17,064	(41,710)	9,855
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	$ 10,577	$ (17,248)	$ 41,970	$ (10,014)

Components of Accumulated Other

Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			$ 1,407,884
Other comprehensive (loss) income before reclassifications			(18,193)	$ (251)
Net losses (gains) reclassified from accumulated other comprehensive loss			8	(140)
Total other comprehensive (loss) income	$ (19,196)	$ 817	(18,185)	(391)
Balance at the end of the period	1,340,027		1,340,027
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(4,500)	(2,119)
Other comprehensive (loss) income before reclassifications			(199)	(391)
Net losses (gains) reclassified from accumulated other comprehensive loss			0	0
Total other comprehensive (loss) income			(199)	(391)
Balance at the end of the period	(4,699)	(2,510)	(4,699)	(2,510)
Unrealized Net Gains (Losses) on Marketable Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			0	140
Other comprehensive (loss) income before reclassifications			(18,115)	0
Net losses (gains) reclassified from accumulated other comprehensive loss			0	(140)
Total other comprehensive (loss) income			(18,115)	(140)
Balance at the end of the period	(18,115)	0	(18,115)	0
Unrealized Net Gains on Foreign Exchange Contracts [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			258	0
Other comprehensive (loss) income before reclassifications			121	140
Net losses (gains) reclassified from accumulated other comprehensive loss			8	0
Total other comprehensive (loss) income			129	140
Balance at the end of the period	387	140	387	140
Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period			(4,242)	(1,979)
Balance at the end of the period	$ (22,427)	$ (2,370)	$ (22,427)	$ (2,370)

Components of Accumulated Oth68

Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 251	$ 166	$ 90
Unrealized Net Gains (Losses) on Marketable Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)				$ 88

Income Tax Effects Related to C

Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ (943)	$ 677	$ (199)	$ (391)
Net change in unrealized (losses) gains on marketable securities, Before-Tax Amount	18,115	0	18,115	228
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	(227)	230	214	230
Other comprehensive (loss) income, Before-Tax Amount	(19,285)	907	(18,100)	(389)
Foreign currency translation adjustments, Tax Effect	0	0	0	0
Other comprehensive (loss) income, Tax Effect	89	(90)	(85)	(2)
Foreign currency translation adjustments, Net	(943)	677	(199)	(391)
Other comprehensive (loss) income, Net	(19,196)	817	(18,185)	(391)
Unrealized Net Gains (Losses) on Marketable Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Marketable securities, net loss arising during the period, Before-Tax Amount	(18,115)	0	(18,115)	0
Marketable securities, net (gain) loss reclassified into income, Before-Tax Amount	0	0	0	(228)
Net change in unrealized (losses) gains on marketable securities, Before-Tax Amount	(18,115)	0	(18,115)	(228)
Marketable securities, net loss arising during the period, Tax Effect	0	0	0	0
Marketable securities, net (gain) loss reclassified into income, Tax Effect	0	0	0	88
Net change in unrealized (losses) gains on marketable securities, Tax Effect	0	0	0	88
Marketable securities, net loss arising during the period, Net	(18,115)	0	(18,115)	0
Marketable securities, net (gain) loss reclassified into income, Net	0	0	0	(140)
Net change in unrealized (losses) gains on marketable securities, Net	(18,115)	0	(18,115)	(140)
Other comprehensive (loss) income, Net			(18,115)	(140)
Derivatives Qualifying as Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	(227)	230	214	230
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	89	(90)	(85)	(90)
Derivatives qualifying as cash flow hedges, net gain (loss), Net	(138)	140	129	140
Other comprehensive (loss) income, Net			129	140
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Before-Tax Amount	(141)	230	201	230
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount	(86)	0	13	0
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	(227)	230	214	230
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect	55	(90)	(80)	(90)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	34	0	(5)	0
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	89	(90)	(85)	(90)
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net	(86)	140	121	140
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net	(52)	0	8	0
Derivatives qualifying as cash flow hedges, net gain (loss), Net	$ (138)	$ 140	$ 129	$ 140

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Pending Litigation [Member] - $ / Violation	6 Months Ended
	Jun. 30, 2016	May 01, 2012
Pegasus Imaging Corporation [Member]
Loss Contingencies [Line Items]
Contingency allegations	The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations, and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud, and negligence
Loss contingency action taken by defendant	Counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation.
Physicians Healthsource Inc [Member]
Loss Contingencies [Line Items]
Damages sought per alleged violation of the TCPA		500

Business Segments - Additional

Business Segments - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2016Segment
Segment Reporting [Abstract]
Number of reportable segments	3
Number of operating segments	5

Revenues and Income from Operat

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting Information [Line Items]
Revenue	$ 386,521	$ 351,718	$ 732,079	$ 686,270
Gross Profit	166,684	143,624	318,582	273,414
Income (loss) from operations	18,574	5,591	30,470	(104)
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	6,008	14,127	25,068	29,571
Gross Profit	(8,359)	(6,223)	(10,618)	(10,429)
Income (loss) from operations	(70,441)	(74,661)	(144,822)	(144,287)
Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	282,254	282,542	553,908	546,417
Gross Profit	121,319	112,995	235,519	211,268
Income (loss) from operations	67,386	57,518	128,403	100,703
Population Health [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	54,026	55,049	108,870	110,282
Gross Profit	38,775	36,852	78,732	72,575
Income (loss) from operations	24,028	22,734	49,288	43,480
Netsmart [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	44,233	0	44,233	0
Gross Profit	14,949	0	14,949	0
Income (loss) from operations	$ (2,399)	$ 0	$ (2,399)	$ 0